Interferon Alfa-2a in the Treatment of Cutaneous T Cell Lymphoma

    Elise A. Olsen, Steven T. Rosen, Robin T. Vollmer, Daina Variakojis, Henry H. Roenigk, Nagwa Diab, J. Zeffren
    Image
    Studysummary This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →